8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A clinical deep-dive into the real limitations, enrollment biases, generalizability gaps, and statistical caveats of the SURPASS-3 trial comparing tirzepatide to insulin degludec in type 2 diabetes.
A detailed methodological breakdown of the SURPASS-3 trial comparing tirzepatide to insulin degludec in type 2 diabetes, covering randomization, blinding, estimand framework, comparator choice, and how each design decision shapes clinical interpretation.
Health-economic analyses of the SURPASS-3 trial comparing tirzepatide vs insulin degludec: cost per QALY, payer coverage, list vs net pricing, and relative value for patients with type 2 diabetes.
Deep-dive into the SURPASS-3 open-label extension: durability of tirzepatide's A1C and weight benefits vs insulin degludec over 52 additional weeks, safety signals, and long-term clinical implications.
A detailed breakdown of SURPASS-3 trial results comparing tirzepatide vs insulin degludec in type 2 diabetes, including effect sizes, confidence intervals, secondary endpoints, and time-course data.
Detailed breakdown of SURPASS-3 pre-specified and post-hoc subgroup analyses by age, sex, BMI, baseline A1C, race, and renal function, with clinical translation for real-world prescribing.
A plain-English deep dive into the SURPASS-3 trial comparing tirzepatide vs insulin degludec in type 2 diabetes, covering methodology, results, limitations, and clinical implications.
A clinical-practice translation of the SURPASS-3 trial comparing tirzepatide vs insulin degludec in type 2 diabetes, covering guideline updates, prescribing shifts, and real-world patient selection.